2595.HK

2026

2026/æ88z

C”8µ„"¿^ %<#¿l-1 *b7

G

“ ” “ ” “ ” “ ” “ ” “ ” “ ” “ ”

G

“ ”

”

ϑ

“

RAS^˝a¯ hR1G iɬ)Q þ$‡/æa„Gö$µ1P /t(‹

Pan RAS4 #¤#·/t(‹iö>‰%4Qu
(Pan RASi)

RMC-6236/æ fr& .b!fiiö>‰
6r$„6â$‡!

2024 12

2025 9

USD 2.3亿

8 8×$‡/æRAS 4 #¤#·"ŒEu/t(‹[6; iö>‰



	No.1	No.2	
KRAS G12C	= >ohi)— "ŒuL {		
KRAS G12D	GFH375 %U8 G12Di"ŒuaM0 i‖"" j$˙TÆIII8 +* iºQ˘F HRS-4642 III		DN022150 III
Pan KRAS	JAB-23E73 I	/	/
Pan RAS	JYP0015/ERAS-0015 (I)	GFH276 $˙TÆ>-G I/II 8 j6â4ä'×a{ HRS-7172	2026 ESMO LBA I ÿ

$$7+# F * "µ$ 3ð8¡ j-˙J‹ (og•RAS ^˝a¯*ƒbZ s Gø‘0t$ $1

Commercial stage		"Þ%j%C-˙g¤=’		Clinical stage	
W* K?#x,´0Ô1s Modality /WK}/zP # „ fp $1	Gø# 7"#x,´ NME QÌB RAS ^˝a¯	RASG >GI[g§			
SIIP (switch II pocket) 4 #¤#· RAS	Fulzerasib (OFF)		KRAS G12C	RMC-6291 (ON)	
	GFH375 (ON/OFF)		KRAS G12D	RMC-9805 (ON)	
	GFH276 (ON)		Pan RAS (ON)	RMC-6236 (ON)	
	GFH603 (KEAP1 }		Novel RAS	RMC-5127 (ON, G12V)	
7"(ý4 ¯!ŁQˇTÆCÛ	FAScon (EGFR Pan RAS ADC}			Unavailable	
SIIP4 #¤#·+#x,´Rh	GFH375+GFH276	RAS+RAS		RMC-9805+RMC-6236	#x,´Rh+ #x,´Rh
RASi+1ŁG7^ %>4	GFH375+GFS202A	* „- #x,´Gö # 7"Qˇ%zG >G		Unavailable	

Advantages h Hedge all MOAs possible, create clinical and commercial synergies

2026/æaM-˙ h % 8 ƒ/ŭ /•$ a j^ $ K¥- 6¡4sRAS ^˝a¯iŧ""/u-†

^¶8 aM-˙ìì# „E"cC" *y"•_%

PART 02

公司管线和项目进展

iº>Z"þ1 I KŁ h NSCLC KRAS G12D
III

G 6" h POC+RP2D KRAS G12D $˙TÆ>-G PDAC,
NSCLC G 6"ił"" vRbRìG¾<NSCLC(„ú)1 Gö¼U8xì |G1XR˙TÆKG1/2D G >GtÔfÚ..Ò465]4‹NSKR"ÚEu/dU) ì;* kÜ, að À

"ÚEu0r%C h
FDA PDAC NSCLC FTD

‚ß"Ú1 hRP2D RMC-6236
Ref. : 2025 ESMO Rev Med

GFH375 ƒ/ü KŁ6â4àaPP_* < "»a{(og•,Øi] %U*ƒ4 %…







KRAS G12D4 #¤#·$˙TÆ>-G 2L+ PDACh GFH375%U8 8r Ä#·cA „8r G 6”

&3	RP2D	9'8 cA	ORR	DCR	PFS	OS	6â4ã8×@
GFH375	600 mg QD	59	40.7%	96.7%	5.52m; 4-m rate: 78.2%	4-m rate: 92.2%	2025 ESMO
DN022150 >Z-v	650 mg QW	31	41.9%	93.5%	/	/	2026 ASCO
INCB161734	1200 mg QD	41	37%	78%	/	/	2026 ASCO GI
TSN1611	1200 mg BID	11	36.4%	72.7%	/	/	2026 ASCO GI
			800-1200 mg BID				
RMC-9805 (zoldonrasib)	1200 mg QD	40	30%	80%	/	/	2025 ASCO GI
HRS-4642 >Z-v	D1 500 mg+ D8 1200 mg, Q3W	24	20.8%	79.2%	4.1m	7.2m	2025 ESMO
ASP3082 (setidegrasib) >Z-v	600 mg QW	21	23.8%	57.1%	3m	10.3m	2026 ASCO GI 2026 NEJM
RNK08954	1200 mg QD	13	15%	85%	/	/	2026 ASCO GI
			200-1200 mg QD				

KRAS G12D4 #¤#·$˙TÆ>-G 2L+ NSCLC h GFH375%U8 8r Ä#·cA „8r G 6”

GFH375	600 mg QD	16	68.8%	93.8%	/	/	2025 WCLC
TSN1611	1200 mg BID	27	44.4%	88.9%	/	/	2026 ASCO
			600-1200 mg BID				
RMC-9805 (zoldonrasib)	1200 mg QD	18	61%	89%	/	/	2025 AACR
HRS-4642 >Z-v	D1 500 mg+ D8 1200 mg, Q3W	38	23.7%	76.3%	5.6 m	13.7 m	2025 ESMO
ASP3082 (setidegrasib) >Z-v	600 mg QW	45	36%	84%	11.3 m	59%	2026 NEJM
RNK08954	1200 mg QD	NA	45%	95%	/	/	2026 ASCO

(o"÷L r:!g h2025 9

3 PDAC

@¸(8f* >-G L %U h GFH276^Ø6”#·cA%þ(<Õ“Gö
P6P9#x/u À RMC -6236

4’4 * c?Q TÆ h RTK G12C

, ¯PK %<,ß"Ú1 6â4àh-˙E"8f-/>MGö@¸(>-G L %U

[4-Q#¢G 6”Gö8r À#·cA	GFH276 8 4 h⁄	RMC-6236 80 mg QD
3P %< W]TRAE	8 [4-Q#¢	
H G+%CF	(„ ‹1 P	1-2

	GFH276 H‘#¿8r å#·cA | }	RMC-6236 RP2D#·cA=ƒ/å 300 mg QD
rG3H G+	>-G ‘ıfæ7hgf% !Ł%C	14% (RASolute 302 Study, 2026 ASCO)
, ¯8&h⁄cA	6â RMC -6236 RP2D (300 mg QD Gö, ¯8&h⁄cA	/

GFH2768r ÀØ6”#·cA%< W |=ƒ/åGö
1› ¯&?0 Dø À RMC-6236

GFH276% P_0r%C-˙8 hRP2Dà % "ŒEu* at0 G9 „%vP17+9”/ŁY¾

CRChiïG0Iƒ-†

- G3 TRAE
- CRC

A%>/]Gkþ



1]a aM"× rP1 7+9” hPDAC „ NSCLC

- II

KROCUS KRAS+EGFR POC

- PI

Q (o]Gkþ

first- in - human

GFS202A GDF15/IL-6%>4 h"ÚŒuk 1ŁG7^ %>4 hŁ% G >G

"ÚŒuk # %<# <›G 6” h GDF15
ASCO6â4à7°J‹$˙TÆG >GGö# <»Ka8óG 6” j

%>a _a4 #¤ $1 hGDF15 IL-6 PD-(L)1
GSF202A>-G 1ŁG7^ %<0 -k"¿G G >GQ TÆ jG 6”8{8 ^÷^ü Mí$˙4

1ŁG7^ 2 Qw ,Q /æ>M h
Hj"åTÆCÛaJ8{8 "¿G >-G Q˘F j4E-˙ ICIatF ,Q

GDF15$˙4 POC%<>Z"|9%4Quponsegromab
II/III GDF15

GDF15$˙4 „IL-6R$˙4 Q˘%z9y#8>-G %4Quvisugromab PD-1
tocilizumab



Nature j 6øLR"å>ZR1G 1ŁG7^ I KŁ jGFS202A]Gkþ7°J‹ ponsegromab]GkþrSfGö#·cA! ^¨0 ¯c?* $



#·cA! ^¨0 ¯c?* $

GFS202A 6 200 mg Q3W /å(„ ¯c?* $ r5% j 5BJ‹GFS202A %a 6«&ðR1G Hj"åGö¯c?#A'í





创新

! 3˚RAS G >G‡ŁG7^ %>4 Gø "µM P1 j3¯a <° /‘0t$ Q˘ F 7+9” ——* "µ$˙TÆ+Q˘%zG >GI[g§8{8 G 6”^÷^ü▹Ø* &3

"ŰŒuk RASi +1ŁG7^ %>4 Q˘%zG >G

GFH375+GFS202A
II IND

GDF15$˙4 +$ G
NCT06989437

RAS+$ G 3 "¿G G >G
NCT07491445, NCT06445062,
RAS+

GFH375+GFH276 h"ÚEuk %~ ¸F 8‹#¤GöRAS 4 #¤#·%>Q˘7+9”

Rev Med

RMC-9805+RMC-6236

- *ORR*
- *G12D+Pan RAS*





"ÚŒuRbRìG¾‰<1ŁG7^ TÆCÛt(‹iö>‰ h$‡/æ÷a0#¢6âGð1P ,= /s[6;

"ÚŒuRbRìG¾‰"%CG7 ýiö>‰

Frost Sullivan



"ÚŒuRbRìG¾‰ÆCÛt(‹iö>‰

Research Nester



Fortune Business Insights, Frost Sullivan



"ÚŒuR1G 1ŁG7^ TÆCÛt(‹iö>‰

Vantage M arket Research



2 26 2027-˙8 h"Þ%j6æ¯M P1I %C[6#



L=_%%z[6U fr j5 aM* at0 G9&, $ /u-†



$$7+k < %4-˙ (oRbRìG7,Ø2026 ,Ø8¡/æ

flp p - Qn01 °l KŁ* ¿I KŁQw ˛ ‹KOL -(#l/ *],(˝